Apimostinel
Apimostinel
Apimostinel (pronounced as "a-pi-most-in-el") is a novel investigational drug that is being studied for its potential use in the treatment of various mental health disorders. It is a glutamate modulator, specifically an NMDA receptor glycine site partial agonist.
Etymology
The term "Apimostinel" is derived from the Greek words "api" meaning "beyond" and "mostinel" meaning "modulator". This is in reference to its function as a modulator of the NMDA receptor, which goes beyond the traditional mechanisms of action of many other psychiatric medications.
Pharmacology
Apimostinel is a glutamate modulator, which means it works by altering the activity of glutamate, a neurotransmitter in the brain. Specifically, it is a partial agonist at the glycine site of the NMDA receptor. This means it binds to this receptor and partially activates it, which can help to regulate glutamate activity and potentially improve symptoms of various mental health disorders.
Clinical Trials
Apimostinel has been studied in several clinical trials for its potential use in the treatment of conditions such as major depressive disorder and post-traumatic stress disorder. However, as of now, it is still considered an investigational drug and is not currently approved for use by the Food and Drug Administration (FDA).
Related Terms
- Glutamate
- NMDA receptor
- Major depressive disorder
- Post-traumatic stress disorder
- Food and Drug Administration
External links
- Medical encyclopedia article on Apimostinel
- Wikipedia's article - Apimostinel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski